{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LABA%2FICS&page=2", "query": { "intervention": "LABA/ICS", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LABA%2FICS&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T13:56:30.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01443845", "title": "Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD", "COPD Exacerbation", "Lung Diseases", "Respiratory Disorders", "Pulmonary Disease", "Chronic Obstructive Lung Diseases", "Chronic Obstructive Airway Disease" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2354, "start_date": "2011-09-30", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2017-04-13", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 217, "location_summary": "Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443845" }, { "nct_id": "NCT04138758", "title": "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COPD" ], "interventions": [ { "name": "Tiotropium bromide + Olodaterol", "type": "DRUG" }, { "name": "LABA/ICS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 42953, "start_date": "2019-11-01", "completion_date": "2019-11-04", "has_results": true, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 1, "location_summary": "Watertown, Massachusetts", "locations": [ { "city": "Watertown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138758" }, { "nct_id": "NCT00706446", "title": "The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "tiotropium bromide", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "Formoterol", "type": "DRUG" }, { "name": "Fluticasone propionate", "type": "DRUG" }, { "name": "budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 255, "start_date": "2008-06", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00706446" }, { "nct_id": "NCT06572228", "title": "Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "ICS/LABA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2024-08-26", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 51, "location_summary": "Bakersfield, California • La Jolla, California • Lancaster, California + 47 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06572228" }, { "nct_id": "NCT04718389", "title": "A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GSK3511294 (Depemokimab)", "type": "BIOLOGICAL" }, { "name": "Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Standard of care (SoC)", "type": "DRUG" }, { "name": "Pre-filled Syringes (PFS)", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1717, "start_date": "2021-01-26", "completion_date": "2025-09-14", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 119, "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718389" }, { "nct_id": "NCT07282886", "title": "VENTURI (VENTilation Using Respiratory Imaging)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI", "type": "DRUG" }, { "name": "Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2026-03-15", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07282886" }, { "nct_id": "NCT03265145", "title": "Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Stiolto Respimat", "type": "DRUG" }, { "name": "ICS (Inhaled Corticosteroid) (Triple therapy)", "type": "DRUG" }, { "name": "LABA (Long-Acting Beta Agonist) (Triple therapy)", "type": "DRUG" }, { "name": "LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 714, "start_date": "2017-09-20", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 90, "location_summary": "Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03265145" }, { "nct_id": "NCT02105974", "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate/Vilanterol", "type": "DRUG" }, { "name": "Vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1621, "start_date": "2014-04-07", "completion_date": "2015-07-08", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 17, "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105974" }, { "nct_id": "NCT02336425", "title": "Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "QGE031", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2015-09", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-08-11", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Kingwood, Texas • Plano, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingwood", "state": "Texas" }, { "city": "Plano", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02336425" }, { "nct_id": "NCT03654976", "title": "Mite Asthma Pediatric Immunotherapy Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allergic Asthma Due to Dermatophagoides Farinae", "Allergic Asthma Due to Dermatophagoides Pteronyssinus", "Allergic Rhinitis Due to House Dust Mite" ], "interventions": [ { "name": "HDM SLIT-tablet", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "ALK-Abelló A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 533, "start_date": "2018-02-22", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2023-10-19", "last_synced_at": "2026-09-04T13:56:30.578Z", "location_count": 7, "location_summary": "Miami, Florida • Columbus, Georgia • Ypsilanti, Michigan + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Ypsilanti", "state": "Michigan" }, { "city": "Bangor", "state": "Pennsylvania" }, { "city": "Verona", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654976" } ] }